NAGE Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
29.8M
-5.4%
31.5M
-7.0%
33.8M
-0.4%
34.0M
+9.2%
31.1M
Cost of Revenue
10.5M
-8.9%
11.5M
-5.2%
12.1M
+0.6%
12.1M
+10.7%
10.9M
Gross Profit
19.3M
-3.3%
20.0M
-8.0%
21.7M
-1.0%
21.9M
+8.4%
20.2M
Operating Expenses
18.6M
+1.2%
18.4M
+4.4%
17.6M
-0.4%
17.7M
+3.8%
17.0M
R&D
1.5M
+2.2%
1.5M
-13.4%
1.7M
-4.7%
1.8M
+14.6%
1.6M
SG&A
17.1M
+1.1%
16.9M
-5.4%
17.9M
+12.5%
15.9M
+2.7%
15.5M
Operating Income
700.0K
-55.6%
1.6M
-61.4%
4.1M
-3.5%
4.2M
+33.0%
3.2M
EBITDA
991.0K
-46.9%
1.9M
-57.5%
4.4M
+1.9%
4.3M
+27.7%
3.4M
Net Income
963.0K
-84.8%
6.3M
+52.9%
4.1M
-9.7%
4.6M
+26.8%
3.6M
EPS (Basic)
$0.01
-87.5%
$0.08
+60.0%
$0.05
-16.7%
$0.06
+20.0%
$0.05
EPS (Diluted)
$0.01
-85.7%
$0.07
+40.0%
$0.05
+0.0%
$0.05
+25.0%
$0.04
Shares (Diluted)
82.5M
-2.4%
84.6M
-1.3%
85.7M
-1.1%
86.6M
+0.4%
86.2M
Niagen Bioscience (NAGE) โ€” Financials